The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Open accessAbstract
BACKGROUND Empagliflozin cardiac benefits in the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial cannot be explained exclusively by its antihyperglycemic activity. OBJECTIVES The hypothesis was that empagliflozin's cardiac benefits are mediated by switching myocardial fuel metabolism away from glucose toward ketone bodies (KB), which improves myocardial energy production. METHODS Heart failure was induced in nondiabetic pigs (n = 14) by 2-h balloon occlusion of the proximal left anterior descending artery. Animals were randomized to empagliflozin or placebo for 2 months. Animals were evaluated with cardiac magnetic resonance imaging and 3-dimensional echocardiography. Myocardial metabolite consumption was analyzed by simultaneous blood sampling from coronary artery and coronary sinus. Myocardial samples were obtained for molecular evaluation. Nonmyocardial infarction animals served as comparison. RESULTS Despite similar initial ischemic myocardial injury in both groups, the empagliflozin group showed amelioration of adverse remodeling at 2 months (lower left ventricular [LV] mass, reduced LV dilatation, less LV sphericity) versus the control group. LV systolic function (LV ejection fraction and echocardiography-derived strains) was improved, as was neurohormonal activation. Compared with nonmyocardial infarction, control animals increased myocardial glucose consumption mainly through anaerobic glycolysis while reducing utilization of free fatty acid (FFA) and branched-chain amino acid (BCAA). Empagliflozin-treated pigs did not consume glucose (reduction in myocardial glucose uptake, and glucose-related enzymes) but instead switched toward utilization of KB, FFA, and BCAA (increased myocardial uptake of these 3 metabolites, and enhanced expression/activity of the enzymes implicated in the metabolism of KB/FFA/BCAA). Empagliflozin increased myocardial ATP content and enhanced myocardial work efficiency. CONCLUSIONS Empagliflozin ameliorates adverse cardiac remodeling and heart failure in a nondiabetic porcine model. Empagliflozin switches myocardial fuel utilization away from glucose toward KB, FFA, and BCAA, thereby improving myocardial energetics, enhancing LV systolic function, and ameliorating adverse LV remodeling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
White, H. D., Norris, R. M., Brown, M. A., Brandt, P. W., Whitlock, R. M., & Wild, C. J. (1987) · Circulation · doi:10.1161/01.cir.76.1.44 · Cited by 2,363
Cohn, J. N., Ferrari, R., & Sharpe, N. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00630-0 · Cited by 2,161
Cahill, G. F. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111258 · Cited by 1,319
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Kimura, I., Inoue, D., Maeda, T., Hara, T., Ichimura, A., Miyauchi, S., Kobayashi, M., Hirasawa, A., & Tsujimoto, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016088108 · Cited by 1,106
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854
Left Ventricular Remodeling in Heart Failure
Konstam, M. A., Kramer, D. G., Patel, A. R., Maron, M. S., & Udelson, J. E. (2011) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2010.10.008 · Cited by 765
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
The Failing Heart Relies on Ketone Bodies as a Fuel
Aubert, G., Martin, O. J., Horton, J. L., Lai, L., Vega, R. B., Leone, T. C., Koves, T., Gardell, S. J., Krüger, M., Hoppel, C. L., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017355 · Cited by 707
Baartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2017) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 661
Bedi, K. C., Snyder, N. W., Brandimarto, J., Aziz, M., Mesaros, C., Worth, A. J., Wang, L. L., Javaheri, A., Blair, I. A., Margulies, K. B., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017545 · Cited by 650
N-Terminal Pro–B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease
Kragelund, C., Grønning, B., Køber, L., Hildebrandt, P., & Steffensen, R. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042330 · Cited by 631
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure
Sun, H., Olson, K. C., Gao, C., Prosdocimo, D. A., Zhou, M., Wang, Z., Jeyaraj, D., Youn, J.-Y., Ren, S., Liu, Y., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.020226 · Cited by 538
Insulin, ketone bodies, and mitochondrial energy transduction
Sato, K., Kashiwaya, Y., Keon, C. A., Tsuchiya, N., King, M. T., Radda, G. K., Chance, B., Clarke, K., & Veech, R. L. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768357 · Cited by 454
Ketone body metabolism and cardiovascular disease
Cotter, D. G., Schugar, R. C., & Crawford, P. A. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00646.2012 · Cited by 440
Théroux, P., Chaitman, B. R., Danchin, N., Erhardt, L., Meinertz, T., Schroeder, J. S., Tognoni, G., White, H. D., Willerson, J. T., & Jessel, A. (2000) · Circulation · doi:10.1161/01.cir.102.25.3032 · Cited by 428
Global Longitudinal Strain to Predict Mortality in Patients With Acute Heart Failure
Park, J. J., Park, J.-B., Park, J.-H., & Cho, G.-Y. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.064 · Cited by 400
Benedict, C. R., Shelton, B., Johnstone, D. E., Francis, G., Greenberg, B., Konstam, M., Probstfield, J. L., & Yusuf, S. (1996) · Circulation · doi:10.1161/01.cir.94.4.690 · Cited by 353
Hung, C.-L., Verma, A., Uno, H., Shin, S.-H., Bourgoun, M., Hassanein, A. H., McMurray, J. J., Velazquez, E. J., Kober, L., Pfeffer, M. A., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.044 · Cited by 305
Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction
Verma, A., Meris, A., Skali, H., Ghali, J. K., Arnold, J. M. O., Bourgoun, M., Velazquez, E. J., McMurray, J. J. V., Kober, L., Pfeffer, M. A., et al. (2008) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2008.05.012 · Cited by 288
Zhang, L., Jaswal, J. S., Ussher, J. R., Sankaralingam, S., Wagg, C., Zaugg, M., & Lopaschuk, G. D. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.000228 · Cited by 269
Metabolic Origins of Heart Failure
Wende, A. R., Brahma, M. K., McGinnis, G. R., & Young, M. E. (2017) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.11.009 · Cited by 207
Prognostic Value of Myocardial Infarct Size and Contractile Reserve Using Magnetic Resonance Imaging
Kelle, S., Roes, S. D., Klein, C., Kokocinski, T., de Roos, A., Fleck, E., Bax, J. J., & Nagel, E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.027 · Cited by 202
Migrino, R., Young, J., Ellis, S., White, H. D., Lundergan, C., Miller, D., Granger, C. B., Ross, A., Califf, R. M., & Topol, E. J. (1997) · Circulation · doi:10.1161/01.cir.96.1.116 · Cited by 189
Schugar, R. C., Moll, A. R., André d’Avignon, D., Weinheimer, C. J., Kovacs, A., & Crawford, P. A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.07.010 · Cited by 186
Mannaerts, H. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.02.030 · Cited by 179
Santos-Gallego, C. G., Vahl, T. P., Goliasch, G., Picatoste, B., Arias, T., Ishikawa, K., Njerve, I. U., Sanz, J., Narula, J., Sengupta, P. P., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.012427 · Cited by 165
Self-citationMarx, N., & McGuire, D. K. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw110 · Cited by 165
Uchihashi, M., Hoshino, A., Okawa, Y., Ariyoshi, M., Kaimoto, S., Tateishi, S., Ono, K., Yamanaka, R., Hato, D., Fushimura, Y., et al. (2017) · Circulation: Heart Failure · doi:10.1161/circheartfailure.117.004417 · Cited by 163
Kappel, B. A., Lehrke, M., Schütt, K. S., Artati, A., Adamski, J., Lebherz, C., & Marx, N. (2017) · Circulation · doi:10.1161/circulationaha.117.029166 · Cited by 157
Jabs, M., Rose, A. J., Lehmann, L., Taylor, J., Moll, I., Sijmonsma, T., Herberich, S. E., Sauer, S. W., Poschet, G., Federico, G., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.029733 · Cited by 154
The diabetic heart utilizes ketone bodies as an energy source
Mizuno, Y., Harada, E., Nakagawa, H., Morikawa, Y., Shono, M., Kugimiya, F., Yoshimura, M., & Yasue, H. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.005 · Cited by 152
Altered systemic ketone body metabolism in advanced heart failure.
Janardhan, A. H., Chen, J., & Crawford, P. A. (2011) · Europe PMC (PubMed Central) · Cited by 79
Kim, Y., Jeon, J. Y., Han, S. J., Kim, D. J., Lee, K. W., & Kim, H. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13297 · Cited by 71
Santos‐Gallego, C. G., García‐Ropero, Á., MANCINI, D. M., Pinney, S., Contreras, J., Fergus, I. V., Abascal, V. M., Moreno, P., Atallah-Lajam, F., Tamler, R., et al. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-06850-0 · Cited by 67
Self-citationDo the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Flores, E., Santos‐Gallego, C. G., Mejia, N. M. D., & Badimón, J. J. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6786-x · Cited by 45
Self-citation
Cited by
PPAR control of metabolism and cardiovascular functions
Montaigne, D., Butruille, L., & Staels, B. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00569-6 · Cited by 942
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
Tan, Y., Zhang, Z., Zheng, C., Wintergerst, K. A., Keller, B. B., & Cai, L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0339-2 · Cited by 835
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 566
Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., et al. (2020) · JAMA · doi:10.1001/jama.2020.1906 · Cited by 531
Metadata
- Authors
- Santos-Gallego, C. G., Requena-Ibanez, J. A., San Antonio, R., Ishikawa, K., Watanabe, S., Picatoste, B., Flores, E., Garcia-Ropero, A., Sanz, J., Hajjar, R. J., Fuster, V., & Badimon, J. J.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 73
- Issue
- 15
- Pages
- 1931-1944
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2936593438
- Cited by
- 651
- References
- 39
- FWCI
- 52.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.